Paratesticular biphasic mesothelioma harboring BRAF V600E mutation 🧬🧬 🚨Check out our case report: The First Report of BRAF V600E Mutation in Paratesticular Mesothelioma @IJSPjournal @MGBpathology ➡️journals.sagepub.com/doi/abs… #GUpath #MolPath

Congrats to our molpath & hemepath classes of 2026 & their amazing PDs! May your careers be brilliant &impactful & in the wise words of our keynote speaker @ACKoongMDPhD : protect your golden hour, have fun & try to have a few memorable dinners w/ friends along the way. 🎓🥂

Great fun presenting at the @IAP_AUS molecular pathology session today! Managed to paraphrase @gradecricketer while drawing parallels between methylation profiling 🧠🧬and DRS 🏏 #molpath #neuropath

As molpath, it’s fun to “rewrite” these entities in terms of molecular alterations: CDH1-deficient tumors: ILC and diffuse gastric ca (classic) Urothelial ca, plasmacytoid variant High grade colorectal (rarely) Gleason 5 prostate ca (also rarely) Others mdpi.com/2072-6694/13/10/232…

A great reminder 💭 that recognizing subtle cytologic clues can directly impact diagnosis, prognosis, and even targeted therapy options. #CytoJ #SalivaryGland #FNAC #SecretoryCarcinoma #MolPath doi.org/10.1111/cyt.70086"

Now there are 3. Thyroid neoplasms harboring a novel OCLN::PRKCI gene fusion doi.org/10.1016/j.humpath.20… doi.org/10.1016/j.modpat.202… #EndocrinePath #moldx #molpath

#BSTPath #MolPath #NewonPath

#MolPath #PathTweetAward2026 Apologies for the delayed repost — I’ve been away from #PathX for a bit and will do my best to catch up over the coming days. Huge congratulations @avash22 on winning the March #PathTweetAward ! Your mTOR tweetorial is outstanding: clear, thoughtful, and highly educational. A very well-deserved recognition for such a valuable contribution to the #PathX community. Many thanks for the time and effort you put into this educational thread. It is truly appreciated 🙏💫💫💫

One gene, many faces 🧬 🎭 #gupath🤝#molpath #pathreads DICER1-associated renal tumors can mimic a wide spectrum of renal neoplasms — another reminder that molecular testing is becoming indispensable in modern renal pathology 🔗 sciencedirect.com/science/ar…

We have an opening for the Molecular Genetic Fellowship Program at MD Anderson for 2027-2028 academic year. Contact info 👇 for anyone who is interested in applying #molpath #pathology mdanderson.org/education-tra…

NYU remains home for the next two years. 🧬 ✨ Grateful and excited to share that I’ve matched in Molecular Genetic Pathology at @NYUGSOM_Path ! 🧬 Looking forward to continuing my journey here after my Hematopathology fellowship. #pathx #molpath

Very pleased to share an online piece brought to you by the CAP Personalized Health Care Committee. By Drs. Pearl Audon and Gagan Mathur. Cell-free DNA in transfusion medicine! 🤯 🧬 🩸 #PathTwitter #molpath #clinpath @Pathologists cap.org/member-resources/art…

#breastpath #Gynpath #Molpath #Diagnexia Excelente oportunidad para ver a la Dra. Janira Navarro en un tema actual : Patología molecular práctica para neoplasias endometriales y mamarias 30 de abril de 2026 | 11:00 a. m. EST | 4:00 p. m. GMT | En español Una sesión enfocada en consideraciones diagnósticas prácticas en patología molecular para neoplasias endometriales y mamarias.¡Webinario en español! A registrarse ↘️

Very pleased to share an online piece brought to you by the CAP Personalized Health Care Committee. By Drs. Jeremy Ward and Matthew Hiemenz. Navigating Discordant MMR/MSI Test Results! #PathTwitter #molpath #surgpath @Pathologists cap.org/member-resources/art…

This educational resource does not constitute medial or legal advise and is not intended for use in the diagnosis and treatment of individual conditions. #AMPtutorials #Molpath #path2path #PathX

(7/7): The discovery of mTOR is particularly fascinating: it began with the study of rapamycin, a natural product isolated from Streptomyces hygroscopicus on Easter Island, and led to the identification of a conserved pathway linking nutrients, growth factors, and energy status to cell growth. This work earned the 2017 Lasker Basic Medical Research Award, awarded to Michael N. Hall for uncovering TOR as a central regulator of cellular growth. #AMPtutorials #Molpath #path2path #PathX

(6/7): Burgeoning evidence shows durable responses to rapamycin analogs (rapalogs) in patients with heavily pretreated metastatic cancers harboring activating mTOR mutations. Accordingly, everolimus and temsirolimus are FDA-approved for certain cancers, and additional inhibitors are in development. However, FRB domain mutations confer resistance to allosteric inhibitors while retaining sensitivity to ATP-competitive kinase inhibitors—an important consideration for precision oncology. #AMPtutorials #Molpath #path2path #PathX

(5/7): In cancer, mTOR functions as a proto-oncogene, and its aberrant activation promotes tumorigenesis. Activating mTOR mutations have been identified in multiple malignancies, including clear cell renal cell carcinoma, endometrial carcinoma, anaplastic thyroid cancer, colorectal adenocarcinoma, and lung adenocarcinoma. These mutations occur across multiple domains and alter kinase activity directly or indirectly. Many clinical laboratories now use next-generation sequencing (NGS) assays to detect mTOR alterations. #AMPtutorials #Molpath #path2path #PathX